CureVac NV
NASDAQ:CVAC

Watchlist Manager
CureVac NV Logo
CureVac NV
NASDAQ:CVAC
Watchlist
Price: 2.99 USD 1.01% Market Closed
Market Cap: 670.7m USD
Have any thoughts about
CureVac NV?
Write Note

Operating Margin
CureVac NV

24.3%
Current
-384%
Average
-7.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
24.3%
=
Operating Profit
132.2m
/
Revenue
543.3m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
DE
CureVac NV
NASDAQ:CVAC
670.8m USD
24%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
318.1B USD
28%
US
Amgen Inc
NASDAQ:AMGN
142.2B USD
19%
US
Gilead Sciences Inc
NASDAQ:GILD
117.1B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.2B USD
40%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
135.7B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD
30%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36.2B EUR
-22%
Country DE
Market Cap 670.8m USD
Operating Margin
24%
Country FR
Market Cap 6T USD
Operating Margin
-17 527%
Country US
Market Cap 318.1B USD
Operating Margin
28%
Country US
Market Cap 142.2B USD
Operating Margin
19%
Country US
Market Cap 117.1B USD
Operating Margin
38%
Country US
Market Cap 105.2B USD
Operating Margin
40%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Country AU
Market Cap 135.7B AUD
Operating Margin
26%
Country US
Market Cap 78.7B USD
Operating Margin
30%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Country NL
Market Cap 36.2B EUR
Operating Margin
-22%
No Stocks Found

CureVac NV
Glance View

Market Cap
670.8m USD
Industry
Biotechnology

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 500 full-time employees. The company went IPO on 2020-08-14. The firm is engaged in the therapeutic development of messenger Ribonucleic Acid (mRNA) and RNA-based vaccines. CureVac AG focuses on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases. The firm's pipeline focuses on three areas: cancer immunotherapy, prophylactic vaccines, and protein-based therapies.

CVAC Intrinsic Value
4.32 USD
Undervaluation 31%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
24.3%
=
Operating Profit
132.2m
/
Revenue
543.3m
What is the Operating Margin of CureVac NV?

Based on CureVac NV's most recent financial statements, the company has Operating Margin of 24.3%.